Veraxa Biotech AG has commenced trading on the Nasdaq Capital Market following the successful completion of its business combination with Voyager Acquisition Corp. The company's common stock and warrants began trading on June 11, 2026, under the ticker symbols 'VRXA' and 'VRXAW', respectively. This milestone is supported by $77.5 million in total financing, comprising a $27.5 million principal amount senior secured note and a $50 million share purchase agreement, which will be used to advance Veraxa's pipeline of oncology drug candidates.

Strategic Business Combination

The transaction, approved by Voyager's shareholders on March 12, 2026, and by Veraxa's shareholders on February 27, 2026, resulted in the merger of Veraxa Biotech AG and Voyager into Veraxa Biotech Holding AG. The surviving entity will operate as Veraxa Biotech AG. Voyager Acquisition Corp. was sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC. The closing of the business combination marks the transition of Veraxa into a publicly traded entity listed on Nasdaq.

Technology and Clinical Data

Veraxa is developing a new generation of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) focused on increasing patient benefit by enlarging the therapeutic window and maximizing safety and efficacy. Central to this strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which enables the creation of conditionally activated, AND-gated therapeutic strategies. This dual-antigen approach targets tumor cells with precision while sparing healthy cells, allowing for the targeting of solid tumors with non-exclusive cancer markers.

Initial data from Veraxa's most advanced BiTAC program were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. The BiTAC-TCE candidate performed as intended in vitro and in vivo, attacking cancer cells featuring both target molecules while sparing cells expressing just one target. The data demonstrated a superior safety profile and matching efficacy compared to a traditional TCE, indicating a potentially improved therapeutic index.

Financial Position and Leadership

The proceeds from the financings will provide Veraxa with the capital to advance its BiTAC-TCE and BiTAC-ADC programs toward clinical development. Christoph Antz, Ph.D., Chief Executive Officer of Veraxa, described the debut as a transformational milestone that positions the company to deliver meaningful value to patients with cancer. Oliver R. Baumann, Chairman of the Veraxa Board and CEO of Xlife Sciences AG, highlighted the strong technology and experienced management team as the foundation for sustainable success.

Warren Hosseinion, M.D., a current member of the Veraxa Board of Directors, noted that the company represents a unique opportunity to fulfill Voyager's mission of scaling a transformational approach in the healthcare industry toward clinical readiness and market approval.